RxDoctor Payments Data

Melissa Mayfield

Family · Crossville, ALNPI 1124591177

Payments from drug & device makers

$329in general payments, 2019–2025

Across 17 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$56
  • Otsuka America Pharmaceutical, Inc.$45
  • Boston Scientific$26
  • AbbVie$22
  • Novartis$21
  • Corcept Therapeutics$20
  • plus $138 from 9 others

What the payments were for

  • Food & beverage$329100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$329 in reported general payments places this provider in the 45th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$53,482
Medicare patients
154
Services billed
3,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$69,165
EliquisApixaban67$51,184
JardianceEmpagliflozin71$44,926
OzempicSemaglutide28$25,892
EntrestoSacubitril/Valsartan18$17,285
FarxigaDapagliflozin Propanediol18$14,320
TrulicityDulaglutide12$13,394
XareltoRivaroxaban23$12,687
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,806
Breo ElliptaFluticasone/Vilanterol30$11,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,872
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$7,582
Spiriva RespimatTiotropium Bromide14$7,241
JanuviaSitagliptin Phosphate13$7,012
LinzessLinaclotide13$6,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$20$82,55973 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$13$28,80549 claims
Novo NordiskOzempic$17$25,89228 claims
NovartisEntresto$21$17,28518 claims
Johnson & JohnsonXarelto$14$12,68723 claims
AbbVieLinzess$22$6,92813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,415 family providers in Alabama.

Other family in Crossville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →